Quantcast
Home > Quotes > FLKS

Flex Pharma, Inc. Common Stock (FLKS) Quote & Summary Data

FLKS 
$0.48
*  
unch
unch
Get FLKS Alerts
*Delayed - data as of Nov. 15, 2018  -  Find a broker to begin trading FLKS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    FLKS After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 0.48 / $ 0.49
Today's High / Low
$ 0.50 / $ 0.4594
Share Volume
605,841
50 Day Avg. Daily Volume
2,085,665
Previous Close
$ 0.48
52 Week High / Low
$ 8.9799 / $ 0.39
Market Cap
8,673,348
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
605,841
50 Day Avg. Daily Volume:
2,085,665

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.57

Trading Range

The current last sale of $0.48 is 23.08% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.50 $ 8.9799
 Low: $ 0.4594 $ 0.39

Company Description (as filed with the SEC)

We are a biotechnology company that is developing innovative and proprietary treatments for muscle cramps, spasms and spasticity associated with severe neurological conditions and exercise-associated muscle cramps. Our lead drug product candidate, FLX-787, is currently being studied in an exploratory Phase 2 clinical trial in Australia in patients with multiple sclerosis, or MS, and in two Phase 2 clinical trials in the United States. One Phase 2 clinical trial in the United States is in patients with motor neuron disease, or MND, primarily with amyotrophic lateral sclerosis, or ALS, who suffer from muscle cramps. FLX-787 is being developed for ALS under fast track designation which was granted by the Food and Drug Administration, or FDA, in July 2017. The other Phase 2 clinical trial in the United States is in patients with Charcot-Marie-Tooth disease, or CMT, who suffer from muscle cramps.  ... More ...  


Risk Grade

Where does FLKS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.4869
Open Date:
Nov. 15, 2018
Close Price:
$ 0.48
Close Date:
Nov. 15, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x